Overweight Multiple Myeloma Patients Show Worse Outcomes with Anti-BCMA CAR-T Therapy in U-Shaped BMI Pattern
Key Insights
A retrospective study of 134 multiple myeloma (search) patients revealed that overweight patients had significantly worse outcomes with anti-BCMA (search) CAR-T therapy compared to normal weight and obese patients.
Overweight patients showed 12-month progression-free survival of 28.8% versus 51.9% for normal weight and 62.6% for obese patients, demonstrating a U-shaped relationship between BMI and treatment efficacy.
The findings suggest an "immunometabolic valley" where overweight status lacks protective benefits seen at either end of the BMI spectrum, warranting further mechanistic research.
A retrospective analysis of 134 multiple myeloma (search) patients treated with anti-BCMA (search) CAR-T therapy has revealed a striking U-shaped relationship between body mass index and treatment outcomes, with overweight patients experiencing significantly worse survival rates compared to both normal weight and obese patients.
The study, conducted at Massachusetts General Hospital between 2016 and 2023, examined patients who received idecabtagene vicleucel (ide-cel; Abecma) in 51.5% of cases, ciltacabtagene autoleucel (cilta-cel; Carvykti) in 23.9%, and investigational therapies in 24.6%. The median BMI of the cohort was 26.7 kg/m², with patients classified as normal weight (<25 kg/m²), overweight (25-29.9 kg/m²), and obese (≥30.0 kg/m²), comprising 36.6%, 32.8%, and 30.6% of the cohort, respectively.
Striking Survival Disparities Across BMI Categories
The most significant finding emerged in 12-month progression-free survival rates, where overweight patients demonstrated markedly inferior outcomes at 28.8% compared to 51.9% for normal weight patients and 62.6% for obese patients (P <.001). This pattern extended to overall survival, with overweight patients achieving 61.4% 12-month survival versus 82.9% for normal weight and 84.2% for obese patients (P =.006).
Complete response rates followed a similar trend, though without statistical significance, at 36.4% for overweight patients compared to 42.9% for normal weight and 56.1% for obese patients (P =.185).
Independent Risk Factor for Poor Outcomes
Univariate Cox regression analysis revealed that overweight patients faced significantly higher risks of disease progression (HR, 2.35; 95% CI, 1.5-3.67; P <.001) and death (HR, 2.38; 95% CI, 1.32-4.28; P =.004) compared to normal weight and obese patients. Importantly, these associations persisted after multivariate adjustment, with overweight status remaining independently associated with worse progression-free survival (HR, 1.69; 95% CI, 1.03-2.77; P =.038) and overall survival (HR, 2.33; 95% CI, 1.08-5.03; P =.031).
The "Immunometabolic Valley" Hypothesis
The researchers propose that this U-shaped relationship reflects an "immunometabolic valley," where overweight patients occupy the most disadvantageous position. "We hypothesized that normal-weight patients have more favorable tumor biology, whereas obesity may paradoxically confer enhanced immunotherapy sensitivity and CAR T-cell therapy efficacy, as seen in other cancers," the authors explained. "Thus, the intermediary overweight state may represent a relatively immunometabolically adverse phenotype without the compensatory benefits seen at either end of the BMI spectrum."
This concept suggests that while normal weight patients benefit from favorable tumor biology and obese patients may gain from enhanced immunotherapy sensitivity, overweight patients lack both advantages.
Study Limitations and Future Directions
The authors acknowledge several limitations of their single-center observational study, including potential selection bias and the crude nature of BMI as a metabolic health indicator. BMI conflates adiposity and lean mass, potentially missing important nuances in individual metabolic profiles.
To address these shortcomings, the researchers emphasize the need for comprehensive body composition analysis in future studies. "Further validation and mechanistic research are essential to elucidate the underlying biological processes," the authors stated. "This research could uncover novel therapeutic targets or modifiable factors to be leveraged to improve CAR T-cell therapy outcomes in MM."
The findings highlight the prognostic significance of host biological determinants and call for mechanistic studies to identify modifiable factors that could optimize CAR-T therapy outcomes across different patient populations with multiple myeloma (search).